
    
      All participants will be phenotype and participants will randomized to randomly assigned
      medications vs phenotype guided medications for obesity. All participants will receive a
      standard intense lifestyle intervention.All participants will be seen at 4 and 12 weeks. At
      the 12-week visit, participants will be unblinded to their "obesity-related phenotype" and
      they could contact their physician to continue a FDA-approved medication as part of clinical
      care. Study team will prospectively follow the patients' weight, waist circumference and use
      of obesity medications every 3 months for 1 year.
    
  